Tenelia Triple Combination Study (TETRIS)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Teneligliptin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Patients with Type 2 Diabetes Mellitus
- Adults aged ≥ 19 years old
- Patients with HbA1c 7%~11% at Screening and Run-in visit
Exclusion Criteria:
-
Sites / Locations
- Samsung Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Teneligliptin
Sitagliptin
Arm Description
20mg qd
100mg qd
Outcomes
Primary Outcome Measures
Change of HbAlc from baseline at Week 24
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02567994
Brief Title
Tenelia Triple Combination Study
Acronym
TETRIS
Official Title
Efficacy and Safety of Teneligliptin Versus Sitagliptin as add-on Therapy to Metformin Plus Glimepiride in T2DM Patinets With Inadequate Glycemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
April 2015 (Actual)
Primary Completion Date
October 2017 (Actual)
Study Completion Date
December 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Handok Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
After a screening, a 2-week, single-blind placebo run-in, 200 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Teneligliptin 20mg or sitagliptin 100mg to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.
Detailed Description
Subjects will visit the centers on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
201 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Teneligliptin
Arm Type
Experimental
Arm Description
20mg qd
Arm Title
Sitagliptin
Arm Type
Active Comparator
Arm Description
100mg qd
Intervention Type
Drug
Intervention Name(s)
Teneligliptin
Intervention Description
Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
Primary Outcome Measure Information:
Title
Change of HbAlc from baseline at Week 24
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with Type 2 Diabetes Mellitus
Adults aged ≥ 19 years old
Patients with HbA1c 7%~11% at Screening and Run-in visit
Exclusion Criteria:
-
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Tenelia Triple Combination Study
We'll reach out to this number within 24 hrs